ストックスクリーナーアプリを入手
3.77
2.08%
-0.08
アフターアワーズ：
3.77
前日終値:
$3.85
開ける：
$3.91
24時間の取引高:
269.43K
Relative Volume:
0.48
時価総額：
$397.67M
収益：
$45.44M
当期純損益:
$-35.43M
株価収益率:
-11.09
EPS:
-0.34
ネットキャッシュフロー:
$-25.39M
1週間 パフォーマンス:
-9.59%
1か月 パフォーマンス:
-19.10%
6か月 パフォーマンス:
-13.33%
1年 パフォーマンス:
-17.86%
1日の値動き範囲:
$3.77
$3.955
1週間の範囲:
$3.77
$4.21
52週間の値動き範囲:
$3.165
$5.26
Maxcyte Inc Stock (MXCT) Company Profile
MXCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
3.77 | 397.67M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-29 | 開始されました | Craig Hallum | Buy |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | BTIG Research | Buy |
| 2021-08-24 | 開始されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | Stephens | Overweight |
| 2021-08-24 | 開始されました | Stifel | Buy |
| 2021-08-24 | 開始されました | Wedbush | Outperform |
| 2021-08-24 | 開始されました | William Blair | Outperform |
すべてを表示
Maxcyte Inc (MXCT) 最新ニュース
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
263,833 Shares in MaxCyte, Inc. (NASDAQ:MXCT) Bought by Rice Hall James & Associates LLC - MarketBeat
MaxCyte Experiences Shift in Major Holdings by BlackRock - TipRanks
BlackRock Increases Stake in MaxCyte to 7.66% - TipRanks
Bio Buyout: MaxCyte Acquires SeQure - Law Street Media
BlackRock Adjusts Holdings in MaxCyte, Inc. - TipRanks
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform - News-Medical.Net
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases - MSN
TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease - Genetic Engineering & Biotechnology News
MaxCyte Signs Licensing Deal With TG Therapeutics For Next-Gen Autoimmune Cell Therapies - Nasdaq
MaxCyte signs SPL deal with TG Therapeutics - ShareCast
MaxCyte Signs Platform License Deal With TG Therapeutics -February 12, 2025 at 05:07 am EST - Marketscreener.com
MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - MSN
MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics -February 12, 2025 at 04:37 am EST - Marketscreener.com
MaxCyte and TG Therapeutics partner on next-gen cell therapy for MS - DirectorsTalk Interviews
MaxCyte Partners with TG Therapeutics for Autoimmune Cell Therapy - TipRanks
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - The Manila Times
Maxcyte Says Enters Strategic Platform License With TG Therapeutics -February 12, 2025 at 02:18 am EST - Marketscreener.com
MaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development - Nasdaq
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell ... - The Bakersfield Californian
Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment - StockTitan
Boston-area diagnostics startup scooped up by Maryland company - The Business Journals
Rockville biotech MaxCyte snaps up Boston-area diagnostics startup SeQure Dx - The Business Journals
MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments - MSN
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - The Manila Times
MaxCyte, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results Release Date and Earnings Call Details - Nasdaq
MaxCyte to Announce 2024 Financial Results and Engage in Key Investor Conference - TipRanks
MaxCyte's Critical Q4 Earnings & Strategic Healthcare Conference Appearance: Key Dates Revealed - StockTitan
BlackRock, Inc. Reduces Stake in MaxCyte Inc: An In-Depth Analys - GuruFocus.com
MaxCyte, Inc. (NASDAQ:MXCT) Shares Bought by Gagnon Securities LLC - MarketBeat
MaxCyte® Acquires SeQure Dx To Broaden Cell Engineering Offerings With On-Target and Off-Target Editing Assessments - Technology Networks
MaxCyte Expands Stock Capital with New Common Stock Issuance - TipRanks
MaxCyte Announces Executive Stock Transaction - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares - MarketBeat
ConnectOne Bancorp (CNOB) Issues Press Release on Acquisition of SeQure Dx by MaxCyte - Defense World
MaxCyte, Inc. Acquires SeQure DX Inc. to Enhance Cell Engineering Offerings - Defense World
MaxCyte director exercises options, sells shares By Investing.com - Investing.com Nigeria
MaxCyte director exercises options, sells shares - MSN
MaxCyte Acquires SeQure Dx - FinSMEs
MaxCyte Buys SeQure Dx for Up to $7M - USA Herald
MaxCyte announces acquisition of SeQure Dx - ShareCast
Market news - Research the market
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) -January 30, 2025 at 10:37 am EST - Marketscreener.com
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire
Cell Engineering Biz MaxCyte Buys Gene Firm For Up To $7M - Law360
MaxCyte buys gene therapy analytics firm SeQure Dx -January 30, 2025 at 08:56 am EST - Marketscreener.com
MaxCyte acquires SeQure Dx for $4.5M at closing, sees accretion - TipRanks
Cell Engineering Group MaxCyte Buys US-based SeQure Dx -January 30, 2025 at 05:05 am EST - Marketscreener.com
MaxCyte Acquires Gene Editing Analytics Company SeQure Dx -January 30, 2025 at 04:25 am EST - Marketscreener.com
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - The Manila Times
MaxCyte Expands Cell Engineering Capabilities with Acquisition of SeQure Dx - TipRanks
Maxcyte Inc (MXCT) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
0.57%
大文字化:
|
ボリューム (24 時間):